ONWARD MEDICAL BV EO -12 (F:63E) — Market Cap & Net Worth
Market Cap & Net Worth: ONWARD MEDICAL BV EO -12 (63E)
ONWARD MEDICAL BV EO -12 (F:63E) has a market capitalization of $190.21 Million (€162.70 Million) as of August 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #16797 globally and #1589 in its home market, demonstrating a -4.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONWARD MEDICAL BV EO -12's stock price €2.34 by its total outstanding shares 69528511 (69.53 Million). See ONWARD MEDICAL BV EO -12 balance sheet quality to understand what proportion of total assets are financed by equity.
ONWARD MEDICAL BV EO -12 Market Cap History: 2021 to 2026
ONWARD MEDICAL BV EO -12's market capitalization history from 2021 to 2026. Data shows change from $812.05 Million to $190.21 Million (-29.00% CAGR). Also see 63E total asset value for a full breakdown of the balance sheet.
ONWARD MEDICAL BV EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONWARD MEDICAL BV EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ONWARD MEDICAL BV EO -12 stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
93.33x
ONWARD MEDICAL BV EO -12's market cap is 93.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $503.16 Million | $104.00K | -$32.77 Million | 4838.09x | N/A |
| 2023 | $239.79 Million | $68.00K | -$36.18 Million | 3526.38x | N/A |
| 2024 | $471.46 Million | $229.00K | -$35.73 Million | 2058.78x | N/A |
| 2025 | $352.78 Million | $3.78 Million | -$41.79 Million | 93.33x | N/A |
Competitor Companies of 63E by Market Capitalization
Companies near ONWARD MEDICAL BV EO -12 in the global market cap rankings as of August 17, 2026. Also see cash efficiency ratio of ONWARD MEDICAL BV EO -12 for how efficiently the company converts equity into cash flow.
Key companies related to ONWARD MEDICAL BV EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #431 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #545 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #557 globally with a market cap of $48.56 Billion USD ( ₩71.66 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $505.75 |
| #431 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $803.48 |
| #545 | Argen-X | BR:ARGX | $49.55 Billion | €730.20 |
| #557 | Samsung Biologics Co Ltd | KO:207940 | $48.56 Billion | ₩1548000.00 |
ONWARD MEDICAL BV EO -12 Historical Marketcap From 2021 to 2026
Between 2021 and today, ONWARD MEDICAL BV EO -12's market cap moved from $812.05 Million to $ 190.21 Million, with a yearly change of -29.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €190.21 Million | -46.08% |
| 2025 | €352.78 Million | -25.17% |
| 2024 | €471.46 Million | +96.61% |
| 2023 | €239.79 Million | -52.34% |
| 2022 | €503.16 Million | -38.04% |
| 2021 | €812.05 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 15th, 2026 the market cap of ONWARD MEDICAL BV EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $190.21 Million USD |
| MoneyControl | $190.21 Million USD |
| MarketWatch | $190.21 Million USD |
| marketcap.company | $190.21 Million USD |
| Reuters | $190.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more